IRADIMED Résultats passés
Passé contrôle des critères 5/6
IRADIMED has been growing earnings at an average annual rate of 27.7%, while the Medical Equipment industry saw earnings growing at 12.9% annually. Revenues have been growing at an average rate of 16.8% per year. IRADIMED's return on equity is 22.3%, and it has net margins of 26.1%.
Informations clés
27.7%
Taux de croissance des bénéfices
25.5%
Taux de croissance du BPA
| Medical Equipment Croissance de l'industrie | 8.9% |
| Taux de croissance des recettes | 16.8% |
| Rendement des fonds propres | 22.3% |
| Marge nette | 26.1% |
| Dernière mise à jour des bénéfices | 30 Sep 2024 |
Mises à jour récentes des performances passées
Recent updates
IRADIMED's (NASDAQ:IRMD) Solid Profits Have Weak Fundamentals
Aug 08
If EPS Growth Is Important To You, IRadimed (NASDAQ:IRMD) Presents An Opportunity
Feb 23Getting In Cheap On IRadimed Corporation (NASDAQ:IRMD) Is Unlikely
Feb 07Should You Investigate IRadimed Corporation (NASDAQ:IRMD) At US$45.06?
Nov 06Calculating The Intrinsic Value Of IRadimed Corporation (NASDAQ:IRMD)
Oct 13At US$41.26, Is It Time To Put IRadimed Corporation (NASDAQ:IRMD) On Your Watch List?
Feb 05Iradimed withdraws FDA filing for new infusion pump; prelim Q3 revenue rises 13% Y/Y
Oct 10IRadimed: Record Revenue Could Translate To Share Price Appreciation
Aug 23Here's Why We Think IRadimed (NASDAQ:IRMD) Is Well Worth Watching
Aug 17iRadimed Non-GAAP EPS of $0.26 beats by $0.02, revenue of $12.7M beats by $0.06M
Jul 29IRadimed: Reduce Equity Beta With Upside Capture
Jul 18IRadimed (NASDAQ:IRMD) Might Be Having Difficulty Using Its Capital Effectively
Jul 13At US$48.60, Is IRadimed Corporation (NASDAQ:IRMD) Worth Looking At Closely?
Feb 05Here's What's Concerning About IRadimed's (NASDAQ:IRMD) Returns On Capital
Jan 12Ventilation des recettes et des dépenses
Comment IRADIMED gagne et dépense de l'argent. Sur la base des derniers bénéfices déclarés, sur une base LTM.
Historique des gains et des recettes
| Date | Recettes | Les revenus | Dépenses G+A | Dépenses de R&D |
|---|---|---|---|---|
| 30 Sep 24 | 71 | 19 | 31 | 3 |
| 30 Jun 24 | 69 | 19 | 30 | 3 |
| 31 Mar 24 | 68 | 18 | 28 | 3 |
| 31 Dec 23 | 66 | 17 | 27 | 3 |
| 30 Sep 23 | 63 | 16 | 26 | 3 |
| 30 Jun 23 | 60 | 15 | 25 | 3 |
| 31 Mar 23 | 56 | 14 | 25 | 3 |
| 31 Dec 22 | 53 | 13 | 23 | 2 |
| 30 Sep 22 | 50 | 13 | 23 | 2 |
| 30 Jun 22 | 48 | 12 | 22 | 2 |
| 31 Mar 22 | 45 | 10 | 21 | 2 |
| 31 Dec 21 | 42 | 9 | 20 | 2 |
| 30 Sep 21 | 38 | 6 | 17 | 2 |
| 30 Jun 21 | 35 | 5 | 17 | 2 |
| 31 Mar 21 | 32 | 1 | 19 | 2 |
| 31 Dec 20 | 32 | 1 | 20 | 2 |
| 30 Sep 20 | 34 | 4 | 23 | 2 |
| 30 Jun 20 | 36 | 5 | 23 | 2 |
| 31 Mar 20 | 39 | 10 | 20 | 1 |
| 31 Dec 19 | 39 | 10 | 20 | 1 |
| 30 Sep 19 | 36 | 8 | 18 | 1 |
| 30 Jun 19 | 34 | 8 | 17 | 1 |
| 31 Mar 19 | 32 | 7 | 16 | 1 |
| 31 Dec 18 | 30 | 6 | 16 | 2 |
| 30 Sep 18 | 29 | 5 | 15 | 1 |
| 30 Jun 18 | 27 | 3 | 15 | 2 |
| 31 Mar 18 | 25 | 2 | 15 | 2 |
| 31 Dec 17 | 23 | 0 | 15 | 2 |
| 30 Sep 17 | 22 | 1 | 14 | 2 |
| 30 Jun 17 | 24 | 3 | 13 | 2 |
| 31 Mar 17 | 29 | 5 | 14 | 2 |
| 31 Dec 16 | 32 | 7 | 14 | 1 |
| 30 Sep 16 | 35 | 8 | 15 | 1 |
| 30 Jun 16 | 35 | 9 | 14 | 2 |
| 31 Mar 16 | 33 | 8 | 13 | 2 |
| 31 Dec 15 | 31 | 8 | 12 | 2 |
| 30 Sep 15 | 26 | 5 | 11 | 2 |
| 30 Jun 15 | 22 | 4 | 10 | 1 |
| 31 Mar 15 | 19 | 3 | 9 | 1 |
| 31 Dec 14 | 15 | 2 | 8 | 1 |
| 30 Sep 14 | 15 | 2 | 7 | 1 |
| 30 Jun 14 | 14 | 2 | 6 | 1 |
| 31 Mar 14 | 12 | 2 | 5 | 1 |
| 31 Dec 13 | 11 | 2 | 5 | 1 |
Des revenus de qualité: IRMD has high quality earnings.
Augmentation de la marge bénéficiaire: IRMD's current net profit margins (26.1%) are higher than last year (25.9%).
Analyse des flux de trésorerie disponibles par rapport aux bénéfices
Analyse de la croissance passée des bénéfices
Tendance des revenus: IRMD's earnings have grown significantly by 27.7% per year over the past 5 years.
Accélération de la croissance: IRMD's earnings growth over the past year (14.1%) is below its 5-year average (27.7% per year).
Bénéfices par rapport au secteur d'activité: IRMD earnings growth over the past year (14.1%) exceeded the Medical Equipment industry 11.7%.
Rendement des fonds propres
ROE élevé: IRMD's Return on Equity (22.3%) is considered high.